Navidea biopharmaceuticals announces presentation of results from its two phase 2b clinical trials in rheumatoid arthritis at upcoming american college of rheumatology annual meeting

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that the results from the company's completed nav3-31 phase 2b clinical study as well as the preliminary results of its ongoing nav3-32 phase 2b study have been accepted for presentation as posters at the annual meeting of the american college of rheumatology (“acr”),
NAVB Ratings Summary
NAVB Quant Ranking